Biologics and biosimilars litigation update

Tune in to the second in our 2020 webinar series on decisions in the US and Europe impacting biologics and biosimilars.

Many of the top-selling drugs worldwide are biologics and several companies are seeking to produce biosimilars to compete in these lucrative markets. However, companies continue to face a great deal of uncertainty due to unresolved legal questions involving the governing statutes and patent rights.

Session 2 of this series focuses on recent key decisions, including:

• Recent Federal Circuit decisions involving biologics and biosimilars.
• Updates in the US “patent thicket” antitrust litigation.
• Recent developments in Europe including Kymab v Regeneron Supreme Court judgment in the UK.